Skip to content

Clinical observation of sphenopalatine ganglion pulse radiofrequency on drug resistant allergic rhinitis

Clinical observation of sphenopalatine ganglion pulse radiofrequency on drug resistant allergic rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058837
Enrollment
Unknown
Registered
2022-04-17
Start date
2022-04-16
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Pulse radiofrequency therapy group:Pulse radiofrequency therapy

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. It conforms to the diagnostic criteria in the Diagnosis and Guidelines for Allergic rhinitis formulated by the Nasal Science Group of Otolaryngology Head and Neck Surgery Branch of Chinese Medical Association in 2016; 2. Criteria for drug-resistant allergic rhinitis: patients whose symptoms cannot be controlled after 4 weeks of nasal spray hormone combined with antihistamine treatment; 3. Can tolerate sphenopalatine ganglion pulse radiofrequency therapy; 4. ASA I - II level; 5. 18-60 years old; 6. The patient signed the informed consent in person.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast-feeding women, menstruating women, and women planning to become pregnant within 3 months; 2. Patients who received other treatments or oral or topical glucocorticoids, antihistamines and immunotherapy within 4 weeks prior to treatment; 3. Congenital nasal malformation, sinus disease, severe nasal septum deviation and nasal polyp; 4. Complicated with specific dermatitis and other refractory diseases or with a history of parasitic infection; 5. Patients complicated with serious cardiovascular and cerebrovascular diseases, patients with liver and renal blood system or malignant tumors, psychiatric patients, diabetes patients, and patients with bleeding tendency; 6. Patients with pacemakers, defibrillators, artificial joints, contraceptive rings, etc. Since MRI is performed in a narrow barrel environment, claustrophobic subjects should not participate in the study.

Design outcomes

Primary

MeasureTime frame
Rhinitis symptom improvement score;Rhinoconjunctivitis quality of life questionnaire, RQLQ;Functional magnetic resonance examination;Serological indicators;

Countries

China

Contacts

Public ContactTian Xuebi

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

tianxb@hust.edu.cn+86 18271886823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026